Radiophamaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment.

Ended Awarded

Contract number
HT009023FG1210051
Awardee
Awarding agency
Obligated
$20,976

Award facts

Contract value 100% obligated
$20,976.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Sterling, VA, USA

Award details come from SAM.gov/FPDS.

About this award

Sofie Co., a subsidiary of Sofie Biosciences, Inc., has been awarded a firm fixed price contract valued at $20,976 by the Defense Health Agency to provide a radiopharmaceutical needed for a prostate cancer patient with metastatic lesions after definitive treatment. Performance will take place in Sterling, Virginia through September 30, 2023. No set aside designation was applied to this procurement, which was issued under an existing blanket purchase agreement call held by the Defense Health Agency for radiopharmaceutical and medical isotope products and services.

Quick answers

Who was awarded contract HT009023FG1210051?

HT009023FG1210051 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on December 12, 2022.

How much is contract HT009023FG1210051 worth?

The government has obligated $20,976 on HT009023FG1210051.

Is contract HT009023FG1210051 an order under another contract?

Yes. HT009023FG1210051 is a BPA call under HT001421A0014, a blanket purchase agreement.

Was contract HT009023FG1210051 competed?

The extent of competition for HT009023FG1210051 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award